For years, Tempus AI has been one of the most closely watched — and most doubted — names in AI-driven precision medicine, a company that built an enormous library of genomic and clinical data but struggled, like much of its sector, to turn that data into consistent profit. On July 30, 2026, the Nasdaq-listed company (TEM) reported second-quarter results that gave skeptics reason to pause: $382.49 million in revenue and a $5.64 million net profit, a sharp reversal from a $42.84 million net loss in the same quarter a year earlier.
From Loss to Profit in One Year
The swing from red to black ink matters more than the raw dollar figures might suggest. AI-diagnostics companies have historically burned cash while scaling their data platforms and sequencing operations, and Wall Street has grown wary of firms that promise profitability perpetually one or two years out. Tempus’s Q2 2026 results gave the company a concrete data point to counter that skepticism, and it responded by raising its full-year 2026 revenue guidance to a range of $1.595 billion to $1.605 billion, alongside an expectation of roughly $65 million in full-year adjusted EBITDA.
Buying Into Cancer Monitoring
Ten days before the earnings report, on July 20, 2026, Tempus announced an agreement to acquire Personalis, a company that specializes in tumor-informed minimal residual disease (MRD) testing — blood tests designed to detect trace amounts of cancer that remain, or return, after treatment. The deal signals consolidation in a fast-growing corner of oncology diagnostics, where companies with strong genomic sequencing and AI-analysis capabilities are increasingly acquiring specialized testing technology rather than building it from scratch. For Tempus, folding Personalis’s MRD expertise into its existing genomic and clinical data platform extends its footprint from initial cancer diagnosis into long-term monitoring of patients after treatment.
A National Rollout for Pharmacogenomics
Alongside the acquisition, Tempus launched its OneOme pharmacogenomics (PGx) testing solution nationally. PGx testing analyzes a patient’s genetic makeup to predict how they will metabolize specific medications, information that can help physicians choose drug doses that are effective while reducing the risk of toxic side effects — a particularly valuable tool for patients on complex medication regimens, such as those undergoing psychiatric treatment or managing multiple chronic conditions. A national launch, rather than a limited pilot, suggests Tempus believes the reimbursement and clinical-adoption landscape for PGx testing has matured enough to support broad rollout.
A Foundation Model Feeds Big Pharma
Tempus also delivered an initial version of its foundation model to AstraZeneca as part of an existing collaboration, a step that underscores how Tempus’s business increasingly straddles two markets: selling diagnostic tests directly to patients and physicians, while also licensing its underlying AI models and data assets to pharmaceutical companies for drug discovery and development. That dual approach — diagnostics plus data licensing — is part of what TIME magazine recognized when it named Tempus to its list of the 10 Most Influential Health and Life Science Companies of 2026.
Not Everyone Is Convinced
Even with a profitable quarter, some investors remain cautious about whether Tempus can sustain profitability as it integrates an acquisition, scales a national PGx launch, and continues investing in foundation-model development for pharma partners — all expensive undertakings running in parallel. A single profitable quarter, after years of losses, is an encouraging signal rather than proof of a durable business model; skeptics will want to see the trend hold for several more quarters before treating Tempus as evidence that AI-diagnostics companies can reliably generate sustained earnings, rather than the more familiar pattern of revenue growth funded by continued losses.
What’s Next
The coming quarters will show whether Tempus can integrate Personalis without disrupting the momentum behind its own profitability, and whether the national OneOme rollout translates into meaningful new revenue rather than a modest add-on. If the raised full-year guidance holds and adjusted EBITDA lands near $65 million, Tempus will have built a genuine case study for how AI-driven genomic diagnostics companies can mature past the venture-fueled growth phase into disciplined, profitable operations — a case study the rest of the sector, still mostly unprofitable, will be studying closely.
